Completed Clinical Trials

Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma

By April 24, 2017 No Comments



Estimated Enrollment: 48

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 7214|H3E-US-JMFZ

Study First Received: May 28, 2003

Last Updated: January 24, 2007

Estimated Primary Completion Date: null


Primary Outcome Measures:

To determine the objective tumor response rate for pemetrexed plus gemcitabine every 21 days in patients with malignant pleural mesothelioma who have not received prior chemotherapy|To assess time to objective tumor response for responding patients;To assess duration of response for responding patients;To assess time to treatment failure;To assess time to progressive disease|To assess progression-free survival;To assess overall survival;To determine toxicities of pemetrexed in combination with gemcitabine in this population

Sponsors and Collaborators:

Eli Lilly and Company

Website Link:

Leave a Reply

Call Now